Expectations trend
FY2028 · fiscal year ending 2028-01-31 · fmp
Veeva Systems (VEEV)
NYSEHealth CareSoftware - ApplicationSnapshot 2026-10-23
$323.04+0.15%
Close 2026-10-23 · 1-day change
NYSEHealth CareSoftware - ApplicationSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.27 → 10.27 EPS · FY ending Jan 31, 2028 · 16 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 16; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-10-31 | ||
| Revenue | — | 935M |
| EPS | — | 2.344 |
| Annual ending 2027-01-31 | ||
| Revenue | — | 3.69B |
| EPS | — | 9.237 |
| Annual ending 2028-01-31 | ||
| Revenue | — | 4.14B |
| EPS | — | |
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain strong market position with successful product launches and acquisitions | New products and acquisitions boost its market position. | Intact | Competitive threats materially slow revenue growth or product adoption | Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-01-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 19, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-quality growth business with robust earnings quality and stable management. The multi-year view is intact, supported by recent results and progress on growth and profitability priorities, though risk is elevated.
Valuation is expensive versus peers, with a 1.86 premium measure and an expectations gap of 0.18. The stretched rating suggests the market already expects strong execution, while the low fragility reading indicates no identified signs of unusually brittle expectations.
Near term, revenue and operating income have grown strongly, and management raised fiscal 2027 revenue guidance while keeping profitability and AI platform work as priorities. A recent earnings beat and a supportive sector backdrop help, but guidance cuts, weaker employment data, and recent peer misses are risks; the snapshot gives a low near-term miss estimate.
Over the next few quarters, the thesis hinges on management delivering its fiscal 2027 growth and profitability goals and turning Veeva Falcon’s early-adopter progress into product adoption. A guidance cut would weaken the setup, while continued strong results from healthcare peers could support sector momentum.
For a 1-to-3-year view, VEEV combines strong execution with a supportive sector backdrop, but its expensive valuation makes sustained delivery important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management figures unavailable.
| A primary condition in Veeva Systems's published investment case. The stated target is >= $9.05 per share. |
| Intact |
| Non-GAAP EPS falls below $8.5 in FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Total revenue at or above $3.635 billion in fiscal year 2027 | A primary condition in Veeva Systems's published investment case. The stated target is >= $3.635 billion. | Intact | Total revenue falls below $3.5 billion in FY27 | Revenue: $927.963M FY2027-Q2; GAAP. Published target: >= $3.635 billion. Target period is not explicitly aligned with this observation. Source published Aug 27, 2026927,963,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2027-Q2 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: c96c7b83-4ba6-4b49-b112-1c8579accf26. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$10.03 → $10.27 · observed estimates
$4.08B → $4.14B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $10.03 | $4,083,915,704 | 16 / 21 |
| 2026-07-25 | $10.03 | $4,083,915,704 | 16 / 21 |
| 2026-07-26 | $10.03 | $4,085,265,024 | 16 / 22 |
| 2026-07-27 | $10.03 | $4,085,265,024 | 16 / 22 |
| 2026-07-28 | $10.03 | $4,085,265,024 | 16 / 22 |
| 2026-07-29 | $10.03 | $4,085,443,520 | 16 / 22 |
| 2026-07-30 | $10.03 | $4,085,443,520 | 16 / 22 |
| 2026-07-31 | $10.03 | $4,085,462,705 | 16 / 22 |
| 2026-08-01 | $10.03 | $4,085,462,705 | 16 / 22 |
| 2026-08-02 | $10.03 | $4,085,462,705 | 16 / 22 |
| 2026-08-03 | $10.03 | $4,085,462,705 | 16 / 22 |
| 2026-08-04 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-05 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-06 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-08 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-09 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-10 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-12 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-13 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-14 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-15 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-16 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-17 | $10.03 | $4,085,282,769 | 16 / 22 |
| 2026-08-18 | $10.03 | $4,085,282,769 | 17 / 22 |
| 2026-08-19 | $10.03 | $4,085,282,769 | 17 / 22 |
| 2026-08-20 | $10.03 | $4,083,908,901 | 17 / 22 |
| 2026-08-21 | $10.03 | $4,083,908,901 | 17 / 22 |
| 2026-08-22 | $10.03 | $4,083,908,901 | 17 / 22 |
| 2026-08-23 | $10.03 | $4,083,908,901 | 17 / 22 |
| 2026-08-24 | $10.03 | $4,083,908,901 | 17 / 22 |
| 2026-08-25 | $10.03 | $4,083,910,181 | 16 / 21 |
| 2026-08-26 | $10.03 | $4,083,910,181 | 16 / 21 |
| 2026-08-27 | $10.03 | $4,083,910,181 | 16 / 21 |
| 2026-08-28 | $10.03 | $4,083,910,181 | 16 / 21 |
| 2026-08-29 | $10.22 | $4,135,573,243 | 16 / 21 |
| 2026-08-30 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-08-31 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-09-01 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-09-02 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-09-03 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-09-04 | $10.22 | $4,135,573,243 | 16 / 20 |
| 2026-09-05 | $10.24 | $4,137,474,964 | 16 / 20 |
| 2026-09-06 | $10.24 | $4,137,474,964 | 16 / 20 |
| 2026-09-07 | $10.24 | $4,137,474,964 | 16 / 20 |
| 2026-09-08 | $10.25 | $4,139,564,964 | 16 / 20 |
| 2026-09-09 | $10.25 | $4,139,564,964 | 16 / 20 |
| 2026-09-10 | $10.25 | $4,140,383,299 | 16 / 20 |
| 2026-09-11 | $10.25 | $4,140,383,299 | 16 / 20 |
| 2026-09-12 | $10.25 | $4,140,383,299 | 16 / 20 |
| 2026-09-13 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-14 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-15 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-16 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-17 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-18 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-19 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-20 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-21 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-22 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-23 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-24 | $10.27 | $4,143,390,349 | 16 / 20 |
| 2026-09-25 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-09-26 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-09-27 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-09-28 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-09-29 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-09-30 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-01 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-02 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-03 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-04 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-05 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-06 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-07 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-08 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-09 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-10 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-11 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-12 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-13 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-14 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-15 | $10.27 | $4,142,563,425 | 16 / 20 |
| 2026-10-16 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-17 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-18 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-19 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-20 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-21 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-22 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-23 | $10.27 | $4,142,571,118 | 16 / 20 |
| 2026-10-24 | $10.27 | $4,142,571,118 | 16 / 20 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 21 Buy / Strong Buy · 8 Hold · 1 Sell / Strong Sell
Recent actions · Sep 25–Oct 24 · 1 recorded
2 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.